New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
06:07 EDTIMGNImmunoGen downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded ImmunoGen citing valuation and keeps a $14 price target for shares. The firm believes success of T-DM1 is now fully priced into shares.
News For IMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for IMGN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use